Gefitinib: a new agent in palliative care. - Wikidata - wikimedia - TriplyDB

Gefitinib: a new agent in palliative care.

Gefitinib: a new agent in palliative care.

http://www.wikidata.org/entity/Q35799732

about

Functional characterization of wild-type and 24 CYP2D6 allelic variants on gefitinib metabolism in vitro.

P2860

Q33609979-C17B09AD-4F1D-4B0D-A963-45380558C7D5

P2860

Gefitinib: a new agent in palliative care.

http://www.wikidata.org/entity/Q35799732

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Gefitinib: a new agent in palliative care.

@ast

Gefitinib: a new agent in palliative care.

@en

type

label

Gefitinib: a new agent in palliative care.

@ast

Gefitinib: a new agent in palliative care.

@en

prefLabel

Gefitinib: a new agent in palliative care.

@ast

Gefitinib: a new agent in palliative care.

@en

P1433

Q35799732-279895A2-82C4-4C36-BEFC-487BB3C41E42

P1476

Q35799732-83CC7744-6E8B-4DD1-AD80-DAFE7DDCA03E

P2093

Q35799732-22FA2FAE-C66C-4370-AD2B-4C637764F04E

P2860

Q35799732-08620918-2E5B-4B38-9475-B4A9A33D445F

Q35799732-0DEDFF8C-ECC8-4B6E-BFBD-43D2E61514E9

Q35799732-0F890880-D7DB-4C10-8A56-E2513929CF1A

Q35799732-12DE5405-039B-4518-B2A3-08DBC4E08F21

Q35799732-1AFC197F-B7FF-467A-A2B5-068676684D31

Q35799732-208249C4-4D52-45A8-9F7D-39656C7636B1

Q35799732-2094FD29-C541-44C3-8AC7-23B903D485B4

Q35799732-2AD029BA-D775-4380-BB22-7A07B956A316

Q35799732-2AFCBD77-6A77-4A4E-AB2B-12110E7917F5

Q35799732-33EE72A6-A824-42F7-804D-2D02770223C8

P304

Q35799732-5FFD88AF-3782-4E1A-8687-C1D9878B189B

P31

Q35799732-899610AB-5708-4258-8C95-6FECA9EA4D12

P356

Q35799732-FE26B0DA-8028-47BE-BED7-24304A73F0F4

P433

Q35799732-20CC1C65-D72A-4ADE-8701-72D544291E34

P478

Q35799732-BB08098F-529F-4E10-8BCF-4823A9387501

P577

Q35799732-CE391770-1F0E-46A2-BE9E-BA4622E140CC

P698

Q35799732-BD1FE81F-54E6-4FF2-8F6E-96CF48ABE352

P356

104990910402100313

P1433

American Journal of Hospice and Palliative Medicine

P1476

Gefitinib: a new agent in palliative care.

@en

P2093

Eric Prommer

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Tyrosine kinase inhibitors-ZD1839 (Iressa).

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.

Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer

Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor.

Severe acute interstitial pneumonia and gefitinib.

P304

222-227

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/104990910402100313

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2004-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15188923

http://www.w3.org/2001/XMLSchema#string